Prices delayed by at least 15 minutes | Print
Evgen Pharma PLC (EVG)
ORD 0.25POpen
0.775p
Previous close
0.775p
Trade high
0.7975p
Volume
794,049
Year high
4.05p
Year low
0.70p
Dividend yield
-
Market capitalisation
£3.31 mn
P/E ratio
-
ISIN
GB00BSVYN304
This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 15/04/2024 | 03:25:34 | 0.776 | 78,418 | 608.52 |
| 15/04/2024 | 03:14:55 | 0.784 | 254,593 | 1,996.01 |
| 15/04/2024 | 03:08:25 | 0.7975 | 1,504 | 11.99 |
| 15/04/2024 | 02:34:09 | 0.775 | 109,534 | 848.89 |
| 15/04/2024 | 12:24:55 | 0.787 | 100,000 | 787.00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.